インフルエンザ治療薬市場- 世界の産業規模、シェア、動向、機会、予測、薬剤タイプ別、流通チャネル別、地域別、競合別、2020～2030年

インフルエンザ治療薬の世界市場は、2024年に9億5,492万米ドルと評価され、予測期間には13億9,222万米ドルに達すると予測され、2030年までのCAGRは6.46%です。

インフルエンザは一般的なウイルス感染症であり、慎重かつ迅速に治療しなければ死に至ることもあります。鼻、喉、肺をひどく冒し、感染性の呼吸器感染症です。インフルエンザウイルスによって引き起こされるインフルエンザを予防する最善の方法は、毎年予防接種を受けることです。鼻水、疲労感、筋肉痛、頭痛、発熱、鼻づまりは、最も典型的なインフルエンザの症状です。市場成長を促進する主な要因は、インフルエンザの罹患率と有病率の増加、世界のヘルスケア支出の増加、公衆衛生に対する意識と関心の高まりであり、これらは予測期間中の市場成長をサポートすると予想されます。

さらに、インフルエンザの流行の増加は、インフルエンザ治療薬市場の成長に寄与する可能性のあるいくつかの意味を持っています。インフルエンザの患者数が増加するにつれて、症状を緩和し、重症度を軽減するための薬剤に対する需要が増加することが予想されます。このような需要の増加は、製薬会社による新しくより効果的なインフルエンザ治療薬の開発・販売を後押しします。2022年1月24日～2月6日にかけて実施された世界保健機関（WHO）の調査によると、約1万2,368人がインフルエンザウイルス陽性と判定されました。さらに、171人（6.4％）がインフルエンザA（H1N1）に感染し、2,483人（93.6％）がインフルエンザA（H3N2）に感染していました。さらに、新薬発見のための研究開発投資の増加は、予測期間中、市場に有利な機会を創出すると予想されます。しかし、市場開拓のための高額な費用や抗ウイルス療法に伴う副作用が、2023～2030年の予測期間を通じて市場の成長を阻害しています。

主な市場促進要因

動物疾病の発生

主な市場課題

抗ウイルス耐性

主要市場動向

万能インフルエンザワクチン

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のインフルエンザ治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤タイプ別（リバビリン、オセルタミビル、リレンザ、ペラミビル、インフルエンザワクチン）
  • 流通チャネル別（病院薬局、小売薬局、オンラインチャネル）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米のインフルエンザ治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のインフルエンザ治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のインフルエンザ治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のインフルエンザ治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのインフルエンザ治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因と課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のインフルエンザ治療薬市場：SWOT分析

第14章 競合情勢

• FACCUSA Laboratories Inc
• Lonza Group Ltd
• Bristol-Myers Squibb Co
• Pfizer Inc.
• GlaxoSmithKline plc
• Novo Nordisk A/S
• Sanofi S.A
• Bayer AG
• Banting Medical Inc
• Cipla Limited

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Influenza Drugs Market was valued at USD 954.92 Million in 2024 and is expected to reach USD 1392.22 Million in the forecast period with a CAGR of 6.46% through 2030. Influenza is a common viral infection that, if not carefully and rapidly treated, can be deadly. It affects the nose, throat, and lungs badly and is an infectious respiratory infection. The best way to prevent the flu, which is brought on by influenza viruses, is to be vaccinated annually. Runny nose, exhaustion, aches in the muscles, headaches, fever, and congestion are the most typical influenza symptoms. The key factors driving the market growth is increasing incidence and prevalence of influenza, rising healthcare expenditure worldwide, and increasing awareness and concern for public health that anticipated to support the market growth during forecast period.

Moreover, the increasing prevalence of influenza can have several implications that may contribute to the growth of the Influenza Drugs Market. As the number of influenza cases rises, there anticipated to be an increased demand for medications to alleviate symptoms and reduce the severity of the illness. This increased demand can drive pharmaceutical companies to develop and market new and more effective influenza drugs. According to a World Health Organisation study performed from January 24 to February 6, 2022, around 12,368 persons tested positive with influenza viruses. Of them, 8,423 (68.1%) were diagnosed with influenza A and 3,945 (31.9%) with influenza B. Furthermore, 171 (6.4%) were infected with influenza A (H1N1), whereas 2,483 (93.6%) were infected with influenza A (H3N2). Additionally, rise in R&D investments for discovery of new drugs is anticipated to create the lucrative opportunity for the market during forecast period. However, the high cost of drug development, and side effects associated with antiviral therapy stifles market growth throughout the forecast period of 2023-2030.

Key Market Drivers

Animal Disease Outbreaks

Antiviral demand is a significant driver in the Influenza Drugs Market, underscoring the critical role of these medications in preventing and treating influenza. Influenza, commonly known as the flu, is a highly contagious respiratory illness caused by influenza viruses, posing a substantial public health threat. Antiviral drugs, such as oseltamivir (Tamiflu) and zanamivir (Relenza), are essential in influenza treatment, functioning by inhibiting viral replication within the body. When administered promptly after symptom onset, these medications can reduce the severity and duration of influenza symptoms.

Beyond symptom alleviation, antivirals play a crucial role in preventing severe complications, especially among high-risk populations like the elderly, young children, and individuals with underlying health conditions. These drugs can significantly lower the risk of hospitalization and death. For instance, during the 2023-2024 influenza season, the Centers for Disease Control and Prevention (CDC) estimated at least 29 million illnesses, 370,000 hospitalizations, and 16,000 deaths due to influenza in the United States. Early antiviral treatment has been shown to reduce the risk of severe outcomes, including death, in hospitalized patients.

In the event of an influenza pandemic, antiviral drugs become a frontline defense. Stockpiling these medications is a crucial component of pandemic preparedness strategies, as they help mitigate virus spread and reduce the burden on healthcare systems. The World Health Organization (WHO) emphasizes the importance of maintaining antiviral stockpiles for both prophylaxis and treatment during influenza pandemics.

The demand for antiviral drugs is global, as influenza is a ubiquitous and seasonally recurrent illness affecting populations worldwide. This consistent demand ensures a stable market for influenza antivirals. Pharmaceutical companies continue to invest in research and development to enhance the effectiveness of existing antiviral drugs and to develop new agents with improved properties, further driving market growth. Government health agencies often provide guidelines and recommendations for antiviral use during influenza outbreaks, contributing to increased demand and usage.

In conclusion, antiviral demand is a pivotal driver in the Influenza Drugs Market due to the essential role these medications play in treating influenza, preventing complications, and preparing for potential pandemics. The continued focus on antiviral development and their widespread use in healthcare systems worldwide ensure that this segment remains a cornerstone of influenza management and public health initiatives.

Key Market Challenges

Antiviral Resistance

Antiviral resistance presents a significant challenge for the Influenza Drugs Market. Influenza viruses have a remarkable ability to mutate rapidly, which can lead to the emergence of strains that are less susceptible to antiviral medications. This phenomenon, known as antiviral resistance, can compromise the effectiveness of commonly used drugs like oseltamivir (Tamiflu) and zanamivir (Relenza). Antiviral resistance can render these medications less effective in treating influenza, diminishing their role in managing the disease. Patients may experience prolonged illness and an increased risk of complications, undermining the value of antiviral treatment. The development and spread of antiviral-resistant strains raise public health concerns. These strains can potentially lead to more severe influenza outbreaks and increased hospitalizations, placing additional burdens on healthcare systems. Antiviral resistance can complicate pandemic preparedness efforts. Stockpiling antiviral drugs in preparation for a potential influenza pandemic may be less effective if the circulating strain becomes resistant, necessitating the development of alternative treatment strategies.

Addressing antiviral resistance requires ongoing research and development efforts to develop new antiviral agents that are effective against resistant strains. This can be resource-intensive for pharmaceutical companies. Continuous surveillance and monitoring of influenza strains are essential to detect and respond to antiviral resistance promptly. This requires coordinated efforts between healthcare agencies and research institutions. In conclusion, antiviral resistance poses a multifaceted challenge for the Influenza Drugs Market. It not only impacts the efficacy of current treatments but also necessitates ongoing research, surveillance, and preparedness to address emerging resistant strains. Mitigating this challenge is crucial to ensure that antiviral drugs remain effective tools in managing influenza and safeguarding public health.

Key Market Trends

Universal Influenza Vaccines

Universal influenza vaccines are emerging as a prominent trend in the Influenza Drugs Market, representing a transformative shift in the approach to influenza prevention and treatment. These vaccines are designed to provide broad and long-lasting protection against multiple strains of influenza viruses, transcending the need for annual vaccine updates that specifically target predicted strains. Several factors are driving the trend of universal influenza vaccines:

The influenza virus is notorious for its ability to mutate and generate new strains. Universal vaccines aim to overcome this challenge by targeting conserved regions of the virus that are less prone to mutation, providing immunity against a broader spectrum of influenza strains. Universal vaccines have the potential to greatly reduce the strain mismatch issue that often occurs with seasonal vaccines. By offering protection against a wider range of strains, they mitigate the impact of unexpected influenza outbreaks and improve overall vaccine efficacy. Universal vaccines can play a crucial role in pandemic preparedness. In the event of a novel influenza strain with pandemic potential, these vaccines offer a more comprehensive defense, as they are not dependent on accurate strain prediction.

The shift away from annual vaccinations to less frequent universal vaccines can improve vaccine compliance and convenience for individuals and healthcare systems, reducing the burden of annual vaccination campaigns. The development of universal influenza vaccines requires extensive research and collaboration among scientists and pharmaceutical companies. This trend fuels innovation in the field and stimulates investments in advanced vaccine technologies.

Key Market Players

• FACCUSA Laboratories Inc
• Lonza Group Ltd
• Bristol-Myers Squibb Co
• Pfizer Inc.
• GlaxoSmithKline plc
• Novo Nordisk A/S
• Sanofi S.A
• Bayer AG
• Banting Medical Inc
• Cipla Limited

Report Scope:

In this report, the Global Influenza Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Influenza Drugs Market, By Drug Type:

• Ribavirin
• Oseltamivir
• Relenza
• Peramivir
• Influenza Vaccines

Influenza Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Channel

Influenza Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Influenza Drugs Market.

Available Customizations:

Global Influenza Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Influenza Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Ribavirin, Oseltamivir, Relenza, Peramivir, Influenza Vaccines)
  • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Influenza Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Influenza Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Influenza Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Influenza Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Distribution Channel

7. Europe Influenza Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Influenza Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. United Kingdom Influenza Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. Italy Influenza Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. France Influenza Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Influenza Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Influenza Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Influenza Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Influenza Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Influenza Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Influenza Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Influenza Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Distribution Channel

9. South America Influenza Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Influenza Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Influenza Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Influenza Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Influenza Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Influenza Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Influenza Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Influenza Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers & Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisition

13. Global Influenza Drugs Market: SWOT Analysis

14. Competitive Landscape

• 14.1. FACCUSA Laboratories Inc
  • 14.1.1. Business Overview
  • 14.1.2. Treatment Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Key Personnel
  • 14.1.5. SWOT Analysis
• 14.2. Lonza Group Ltd
• 14.3. Bristol-Myers Squibb Co
• 14.4. Pfizer Inc.
• 14.5. GlaxoSmithKline plc
• 14.6. Novo Nordisk A/S
• 14.7. Sanofi S.A
• 14.8. Bayer AG
• 14.9. Banting Medical Inc
• 14.10.Cipla Limited

15. Strategic Recommendations

16. About Us & Disclaimer